Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A 2A Adenosine Receptor Antagonists
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Gibae Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Ribose, Adenosine A2 Receptor Antagonists, Adenosine, Receptor, Adenosine A2A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Previous molecular dynamics simulations of hA2AAR with 2b and structure-activity relationship (SAR) analyses prompted us to synthesize diol-, deoxy-, fluoro-, and methoxy-derivatives (4) in a regio- and stereoselective manner, modifying the ribose moiety to enhance potency and selectivity at hA2AAR. SAR analysis revealed that the presence of at least one hydroxyl group at either the R2 or R4 position is preferred for hA2AAR binding, and inversion of the R4 hydroxyl group significantly reduced binding affinity at hA3AR. Alteration of the hydroxyl groups in the ribose moiety showed that hA3AR favored diol derivatives, and the following trend was observed at hA2AAR: Ki,hA2A, diol ≈ deoxy < fluoro < methoxy. Among the synthesized derivatives, the deoxy derivative 4d demonstrated exceptional in vitro potency at hA2AAR (Ki,hA2A = 0.36 ± 0.05 nM) and functional efficacy. Additionally, 4d exhibited promising pharmacokinetic properties, and in vivo efficacy assays confirmed its potential as an orally available immune checkpoint inhibitor candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
- Department of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States.
- Future Medicine Co. Ltd, 54 Changup-ro, Sujeong-gu, Seongnam, Gyeonggi-do 13449, Republic of Korea.
- HK inno.N Corp., Seoul 04551, Republic of Korea.
- Preclinical Research Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
ORCID-Profile: Gibae Kim, Lak Shin Jeong
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, G., Kim, S. W., Choi, H., Kim, J. Y., Ahn, S. Y., Lee, J. H., Lee, J. E., Jeon, Y. H., & Jeong, L. S. (2025). Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A 2A Adenosine Receptor Antagonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01774
Vancouver
Kim G, Kim SW, Choi H, Kim JY, Ahn SY, Lee JH, et al. Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A 2A Adenosine Receptor Antagonists. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01774
BibTeX
@article{Kim2025,
author = {Kim, Gibae and Kim, Seung Woo and Choi, Hongseok and Kim, Ji Yong and Ahn, Sang Yeop and Lee, Jong Hyun and Lee, Jae-Eon and Jeon, Yong Hyun and Jeong, Lak Shin},
title = {Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A 2A Adenosine Receptor Antagonists},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01774}
}
EUVIMED